PRXL2AP2

Across TCGA pan-cancer cohorts, PRXL2AP2 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated PRXL2AP2 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PRXL2AP2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRXL2AP2 expression acts as an unfavorable survival marker, although some lineages such as ACC and PAAD show a favorable association.

LIHC, ACC, and COAD are the cancer types where PRXL2AP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Quartile	All	0.305	0.485	<.001	72	view →
ACC	OS	Quartile	II,III,IV	1.000	0.287	<.001	53	view →
COAD	DFS	Quartile	III,IV	0.533	0.713	.004	42	view →
PAAD	OS	Quartile	All	0.829	0.486	.001	36	view →
CHOL	DFS	Tertile	III,IV	0.779	0.152	.013	35	view →
LGG	OS	Median	All	0.942	0.854	<.001	31	view →
THYM	DFS	Median	II,III,IV	0.878	0.598	.008	30	view →
CESC	DFS	Median	All	0.883	0.767	.002	20	view →
ESCA	DFS	Median	IV	0.205	0.634	.006	18	view →
READ	OS	Tertile	All	1.000	0.329	.009	13	view →
LUAD	DFS	Quartile	II,III,IV	0.770	0.579	.012	13	view →
SARC	OS	Tertile	All	0.431	0.769	.001	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

PRXL2AP2–LIHC (DFS)

Open the LIHC breakdown →